9350 Wilshire Blvd.
Suite 203
Beverly Hills, CA 90212
February 8, 2021
Via EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:                                 Tim Buchmiller
GT Biopharma, Inc.
Registration Statement on Form S-1
CIK No. 0000109657
SEC Registration No. 333-251311
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-251311) (the “Registration Statement”) of GT Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on February 10, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP by calling Roger Bivans at (214) 978-3095.
Thank you for your assistance with this matter.
Very truly yours,
/s/ Michael Handelman
Michael Handelman
Chief Financial Officer
Click here to enter Sender1 Email Address.